Nirmesh Patel

Scientist | Founder | Investor at Amino Collective

📍 United Kingdom🔄 Updated September 2026💼 9 investments📅 9 years investing🗓 Last invested Apr 2026
VC🌍 United KingdomInvested this year
9
Total investments
2
Early stage
2
Mid stage
2
Late stage
9y
Years active

Portfolio

9 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Observer
Dec 2024
The traditional drug development pipeline is marred by high failure rates and inefficiencies, largely due to unreliable and non-translating research models. VALID focuses on addressing this critical issue using advanced/complex hiPSC-derived models with increased predictive validity. Transforming Drug Development with VALID Techbio 2.0: Predictive Validity/Efficacy at Scale Better Data = Better Targets = Successful Drug Discovery.
Board Observer
Aug 2024
Lir is an AI viral vector company. Our approach is to revolutionise gene therapy by tackling dose reduction, tissue targeting and immune evasion all at once through state-of-the-art AI modelling and a lab-in-the-loop screening pipeline. Using our nAAVigator AI pipeline we’re engineering viral vectors for gene therapy, starting with AAV. Our goal is to completely resurface viral vectors, enabling therapies that would be otherwise impossible.
Investor
Jun 2024
Amino Collective’s primary investment focus lies within the realms of health and bio. We help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. We invest in early-stage ventures that have a European focus and the ambition to scale globally. Get in touch: hi@aminocollective.com
Board Observer
Nov 2023
Orbillion is a B2B cultivated meat technology company that brings commercially-viable meat to the ever-growing $211B global ground beef market. Orbillion has developed a game-changing algorithm for the scale-up of cultivated meat that makes commercializing low-cost cultivated beef possible. The Orbillion founders bring more than 35 years of combined experience in biopharma bioprocessing, optimizing the very systems required to commercialize cultivated meat. Orbillion is backed by The Venture Collective, Y Combinator, At One Ventures, Venture Souq, and Metaplanet. Learn more and partner with us at www.orbillion.com.
Board Observer
Sep 2023
Unlocking the potential of macrocycle drug discovery through machine learning and massively parallel synthesis
late stageBiotechnology
Board Observer
Jan 2023
A world-leading provider of insect farms and insect technology • Our mission is to accelerate a global transition to sustainable protein, using insects and technology.
late stageBiotechnology
Board Member
Nov 2022
Coding Bio is building next-gen multi-specific T-cell engagers for the most challenging to treat indications in oncology and beyond
early stageBiotechnology
Investor
Jul 2017
This is a catchall company for the doers, the thinkers, and the innovators.
Experience · 13 entries
All (13)
Investments (9)
Founder (1)
Board (6)
2026
2024
Board Observer
Dec 2024
The traditional drug development pipeline is marred by high failure rates and inefficiencies, largely due to unreliable and non-translating research models. VALID focuses on addressing this critical issue using advanced/complex hiPSC-derived models with increased predictive validity. Transforming Drug Development with VALID Techbio 2.0: Predictive Validity/Efficacy at Scale Better Data = Better Targets = Successful Drug Discovery.
Board Observer
Aug 2024
Lir is an AI viral vector company. Our approach is to revolutionise gene therapy by tackling dose reduction, tissue targeting and immune evasion all at once through state-of-the-art AI modelling and a lab-in-the-loop screening pipeline. Using our nAAVigator AI pipeline we’re engineering viral vectors for gene therapy, starting with AAV. Our goal is to completely resurface viral vectors, enabling therapies that would be otherwise impossible.
Investor
Jun 2024
Amino Collective’s primary investment focus lies within the realms of health and bio. We help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. We invest in early-stage ventures that have a European focus and the ambition to scale globally. Get in touch: hi@aminocollective.com
2023
Board Observer
Nov 2023
Orbillion is a B2B cultivated meat technology company that brings commercially-viable meat to the ever-growing $211B global ground beef market. Orbillion has developed a game-changing algorithm for the scale-up of cultivated meat that makes commercializing low-cost cultivated beef possible. The Orbillion founders bring more than 35 years of combined experience in biopharma bioprocessing, optimizing the very systems required to commercialize cultivated meat. Orbillion is backed by The Venture Collective, Y Combinator, At One Ventures, Venture Souq, and Metaplanet. Learn more and partner with us at www.orbillion.com.
Show all 13 entries ↓
Investment activity
2017–2026 · 9 investments
2017120221202332024320261
Recent (last 2 years)Earlier